Zacks Investment Research lowered shares of Orthopediatrics (NASDAQ:KIDS) from a hold rating to a sell rating in a research report report published on Wednesday, March 14th.
According to Zacks, “OrthoPediatrics Corp. is a medical device company. It markets surgical systems for trauma and deformity, bone fractures and reconstruction procedures. OrthoPediatrics Corp. is based in NEW YORK. “
Several other brokerages have also weighed in on KIDS. BTIG Research reiterated a buy rating and set a $24.00 price objective on shares of Orthopediatrics in a report on Friday, January 5th. BidaskClub lowered shares of Orthopediatrics from a hold rating to a sell rating in a report on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $23.67.
KIDS stock traded down $0.18 during midday trading on Wednesday, hitting $16.34. The stock had a trading volume of 22,276 shares, compared to its average volume of 40,057. Orthopediatrics has a 1-year low of $14.00 and a 1-year high of $23.00. The company has a debt-to-equity ratio of 0.53, a quick ratio of 5.29 and a current ratio of 7.35.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Next Century Growth Investors LLC acquired a new position in shares of Orthopediatrics during the fourth quarter valued at about $2,321,000. AWM Investment Company Inc. acquired a new position in shares of Orthopediatrics during the fourth quarter valued at about $8,816,000. Monarch Partners Asset Management LLC acquired a new position in shares of Orthopediatrics during the fourth quarter valued at about $339,000. Driehaus Capital Management LLC acquired a new stake in shares of Orthopediatrics in the 4th quarter worth about $7,682,000. Finally, Lombard Odier Asset Management USA Corp acquired a new stake in shares of Orthopediatrics in the 4th quarter worth about $624,000. Hedge funds and other institutional investors own 32.34% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/orthopediatrics-kids-rating-lowered-to-sell-at-zacks-investment-research.html.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.
Get a free copy of the Zacks research report on Orthopediatrics (KIDS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.